TESLAC
LOE ApproachingNDAORALTABLET
Approved
May 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESLAC is an oral small-molecule tablet approved by Bristol Myers Squibb in 1970 for an indication no longer prominently marketed. The mechanism of action and specific therapeutic indication are not currently documented in available data.
LOE Approaching
This legacy product approaching loss of exclusivity shows minimal commercial activity and likely reduced team investment; roles are primarily focused on managed decline rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TESLAC offers minimal career growth opportunity as a legacy product in decline; roles focus on managing discontinuation, generic transitions, or regulatory wind-down. Professional development and visibility are limited compared to growth-stage products.
Brand Manager (managed decline)Field Sales (maintenance)
Worked on TESLAC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.